Track ATOS and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$20.67M
Enterprise Value-$20.59M
Revenue (TTM)-
Net Income (TTM)-$34.77M
Free Cash Flow (TTM)-$29.79M
Financial Health
Cash$41.30M
Net Debt-$41.26M
Debt Ratio0
Debt to Equity0
Interest Coverage-
Valuation (TTM)
Price to Sales-
Price to Earnings-0.59
EV to EBITDA0.56
Price to Book0.53
Price to Free Cash Flow-0.69
Margins (TTM)
Gross Profit Margin-
EBITDA Margin-
Operating Income Margin-
Net Income Margin-
Free Cash Flow Margin-
Returns (5Y Avg)
Return on Invested Capital-41.01%
Return on Assets-36.59%
Return on Equity-38.85%
Return on Total Capital-41.01%
Return on Capital Employed-41.17%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue0.00%
Diluted EPS83.15%
Total Debt-87.74%
Capital Expenditures19.68%
Free Cash Flow-96.47%
CAGR (3Y)
Revenue0.00%
Diluted EPS-19.69%
Total Debt0.00%
Capital Expenditures-5.20%
Free Cash Flow-99.52%
CAGR (1Y)
Revenue0.00%
Diluted EPS-49.95%
Total Debt0.00%
Capital Expenditures21.05%
Free Cash Flow-100.00%
$2.43+$0.03|+1.23%
Last updated: Jul 22, 4:00 PM ET
52W High$19.35
52W Low$1.70
50D SMA$3.46
200D SMA$7.41
Volume25.75K
Atossa Genetics Inc
448 NW Market Street, Seattle, WA, United States, 98107
IPO
2012
Employees
16
Industry
Biotechnology
Sector
Healthcare
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20250+1
1
Analyst Ratings
1 analysts covering
Buy100%recommend buy
Buy
1
Hold
0
Sell
0